

Thursday 16 April 2009

Chris Murphy
ASX Markets Supervision Pty Ltd
Adviser, Issuers, Melbourne
Level 45, Rialto South Tower
525 Collins Street
Melbourne VIC 3000

Dear Chris,

Price Query

We refer to your email received on Wednesday 15th April 2009 in relation to the increase in the price of Prima Biomed Limited shares. We provide the following response to your queries:

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?
No.
2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?
Not applicable.
3. Is there any reason to think that there may be a change in the operating loss before abnormal items and income tax so that the figure for the financial year ended 30 June 2009 would vary from the previous corresponding period by more than 15%? If so, please provide details as to the extent of the likely variation.
No.
4. Is there any reason to think that the Company may record any material abnormal or extraordinary item for the financial year ended 30 June 2009? If so, please provide details.
No.
5. Is there any other explanation that the Company may have for the price change in the securities of the Company.
Dendreon Corporation on the NASDAQ (DNDN) released positive results in the IMPACT pivotal trial for their prostate cancer Vaccine. Prima Biomed and its Ovarian Cancer Vaccine CVac™ have no official relationship with Dendreon Corporation.
6. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.
The Company continues to comply with all ASX Listing Rules.

Yours sincerely



Robert Kleine
Company Secretary
Thursday 16th April 2009

For personal use only



ASX Markets Supervision Pty
Ltd
ABN 26 087 780 489
Level 45
South Tower
525 Collins Street
Melbourne VIC 3000
GPO Box 1784
Melbourne VIC 3001
Telephone 61 3 9617 8656
Facsimile 61 3 9614 0303
www.asx.com.au

15 April 2009

Mr Martin Rogers
Executive Director
Prima Biomed Limited

By e-mail only

Dear Mr Rogers

Prima Biomed Limited (the "Company") RE: PRICE QUERY

We have noted a change in the price of the Company's securities from 1.6 cents at close on 9 April 2009 to 2.8 cents at close of trading today. We have also observed larger than normal volumes of trades during this period.

In light of the price change, please respond to each of the following questions.

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?

Please note that as recent trading in the Company's securities could indicate that information has ceased to be confidential, the Company is unable to rely on the exceptions to listing rule 3.1 contained in listing rule 3.1A when answering this question.

2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be made immediately, you need to contact us to discuss this and you need to consider a trading halt (see below).

3. Is there any reason to think that there may be a change in the operating loss before abnormal items and income tax so that the figure for the financial year ended 30 June 2009 would vary from the previous corresponding period by more than 15%? If so, please provide details as to the extent of the likely variation.
4. Is there any reason to think that the Company may record any material abnormal or extraordinary item for the financial year ended 30 June 2009? If so, please provide details.
5. Is there any other explanation that the Company may have for the price change in the securities of the Company?

For personal use only

6. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.

Your response should be sent to me by e-mail at chris.murphy@asx.com.au or by facsimile on facsimile number 9614 0303. It should not be sent to the Company Announcements Office.

Unless the information is required immediately under listing rule 3.1, a response is requested as soon as possible and, in any event, not later than half an hour before the start of trading (ie before 9.30 a.m. EST) on Thursday 16 April 2009.

Under listing rule 18.7A, a copy of this query and your response will be released to the market, so your response should be in a suitable form and separately address each of the questions asked. If you have any queries or concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. The exceptions to this requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance Note 8 – Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given to ASX under listing rule 3.1 your obligation is to disclose the information immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to question 1 is yes and an announcement cannot be made immediately, you should consider a request for a trading halt in the 's securities. As set out in listing rule 17.1 and Guidance Note 16 – Trading Halts, we may grant a trading halt at your request. We may require the request to be in writing. We are not required to act on your request. You must tell us each of the following.

- The reasons for the trading halt.
- How long you want the trading halt to last.
- The event you expect to happen that will end the trading halt.
- That you are not aware of any reason why the trading halt should not be granted.
- Any other information necessary to inform the market about the trading halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. If a trading halt is requested and granted and you are still unable to reply to this letter before the commencement of trading, suspension from quotation would normally be imposed by us from the commencement of trading if not previously requested by you. The same applies if you have requested a trading halt because you are unable to release information to the market, and are still unable to do so before the commencement of trading.

If you have any queries regarding any of the above, please let me know.

For personal use only

Yours sincerely,

Sent by electronic means without signature

Chris Murphy

Adviser, Issuers (Melbourne)

For personal use only